Effect of Ring Fluorination on the Pharmacology of Hallucinogenic Tryptamines
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
A series of fluorinated analogues of the hallucinogenic tryptamines N,N-diethyltryptamine (DET), 4-hydroxy-N,N-dimethyltryptamine (4-OH-DMT, psilocin), and 5-methoxy-DMT was synthesized to investigate possible explanations for the inactivity of 6-fluoro-DET as a hallucinogen and to determine the effects of fluorination on the molecular recognition and activation of these compounds at serotonin receptor subtypes. The target compounds were evaluated using in vivo behavioral assays for hallucinogen-like and 5-HT(1A) agonist activity and in vitro radioligand competition assays for their affinity at 5-HT(2A), 5-HT(2C), and 5-HT(1A) receptor sites. Functional activity at the 5-HT(2A) receptor was determined for all compounds. In addition, for some compounds functional activity was determined at the 5-HT(1A) receptor. Hallucinogen-like activity, evaluated in the two-lever drug discrimination paradigm using LSD-trained rats, was attenuated or abolished for all of the fluorinated analogues. One of the tryptamines, 4-fluoro-5-methoxy-DMT (6), displayed high 5-HT(1A) agonist activity, with potency greater than that of the 5-HT(1A) agonist 8-OH-DPAT. The ED(50) of 6 in the two-lever drug discrimination paradigm using rats trained to discriminate the 5-HT(1A) agonist LY293284 was 0.17 micromol/kg, and the K(i) at [(3)H]8-OH-DPAT-labeled 5-HT(1A) receptors was 0.23 nM. The results indicate that fluorination of hallucinogenic tryptamines generally has little effect on 5-HT(2A/2C) receptor affinity or intrinsic activity. Affinity at the 5-HT(1A) receptor was reduced, however, in all but one example, and all of the compounds tested were full agonists but with reduced functional potency at this serotonin receptor subtype. The one notable exception was 4-fluoro-5-methoxy-DMT (6), which had markedly enhanced 5-HT(1A) receptor affinity and functional potency. Although it is generally considered that hallucinogenic activity results from 5-HT(2A) receptor activation, the present results suggest a possible role for involvement of the 5-HT(1A) receptor with tryptamines.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“which may be a necessary property of effective hallucinogens.”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [14]
In the citing paper
“The corresponding Ki values against [123I]-DOI indicated ten-fold higher affinity at 5HT2A sites [10,14], which is presumably indicative of the greater competition between an agonist drug at agonist-labelled receptors, as has been established for the case of dopamine D2/3 receptors [46].”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [14]
Citations
Cites
A SIMPLIFIED METHOD OF EVALUATING DOSE-EFFECT EXPERIMENTS
LITCHFIELD, J. T., & WILCOXON, F. (1949) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)03549-9 · Cited by 7,812
How good is fluorine as a hydrogen bond acceptor?
Howard, J. A. K., Hoy, V. J., O'Hagan, D., & Smith, G. T. (1996) · Tetrahedron · doi:10.1016/0040-4020(96)00749-1 · Cited by 737
Titeler, M., Lyon, R. A., & Glennon, R. A. (1988) · Psychopharmacology · doi:10.1007/bf00176847 · Cited by 343
Schreiber, R., Brocco, M., Audinot, V, Gobert, A., Veiga, S., & Millan, M. J. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)09485-6 · Cited by 300
CYCLOPENTADIENYL COMPOUNDS OF Sc, Y, La, Ce AND SOME LANTHANIDE ELEMENTS
Wilkinson, G., & Birmingham, J. M. (1954) · Journal of the American Chemical Society · doi:10.1021/ja01652a114 · Cited by 272
Human psychopharmacology of N,N-dimethyltryptamine
Strassman, R. J. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(96)00081-2 · Cited by 261
Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes
Mckenna, D. J., Repke, D. B., Lo, L., & Peroutka, S. J. (1990) · Neuropharmacology · doi:10.1016/0028-3908(90)90001-8 · Cited by 192
Characteristics of C-F Systems
Smart, B. E. (1994) · Organofluorine Chemistry · doi:10.1007/978-1-4899-1202-2_3 · Cited by 187
Inter-animal olfactory cues in operant drug discrimination procedures in rats
Extance, K., & Goudie, A. J. (1981) · Psychopharmacology · doi:10.1007/bf00426467 · Cited by 170
Drug discrimination studies with MDMA and amphetamine
Oberlender, R. A., & Nichols, D. (1988) · Psychopharmacology · doi:10.1007/bf00212770 · Cited by 152
Self-citation
Research works printed but not linked: 32
- LeBars D., 1987, Appl. Radiat. Isot., 38, 1077
- Kirk K. L, 1975, J. Org. Chem., 41, 2376
- Kirk K. L, 1976, J. Heterocycl. Chem., 13, 1256
- Janssen P. A, 1965, Int. Rev. Neurobiol., 8, 263
- Smart B. E., 1994, Organofluorine Chemistry: Principles and Commercial Applications (Topics in Applied Chemistry), 88
- Park B. K., 1994, Drug Metab. Rev., 26, 643
- Howard J. A. K., 1996, Tetrahedron, 52, 12622
- Bentov M., 1962, J. Chem. Soc., 2825, 2827
- Aldred R., 1994, J. Chem. Soc., Perkin Trans. 1, 1823, 1831
- Adams R. E., 1991, Synth. Commun., 12, 681
- Speeter M. E., 1954, J. Am. Chem. Soc., 76, 6210
- Chen C., 1994, J. Org. Chem., 59, 3741
- Hoggett J. G., 1969, Chem. Commun., 605, 606
- Desaty D., 1964, Croat. Chem. Acta, 36, 109
- Arnt J, 1989, Pharmacol. Toxicol., 64, 172
- Nichols D. E., 1997, Handbook of Experimental Pharmacology. Serotoninergic neurons and 5-HT Receptors in the CNS, 585
- Marona-Lewicka D., 1997, Soc. Neurosci. Abstr., 23
- Kleven M. S., 1997, J. Pharmacol. Exp. Ther., 282, 759
- Darmani N. A., 1996, Pharmacol. Biochem. Behav., 55, 10
- Darmani N. A, 1998, J. Neural Transm., 105, 643
- Strassman R. J, 1996, Behav. Brain Res., 73, 124
- Schreiber R., 1995, J. Pharmacol. Exp. Ther., 273, 112
- Glennon R. A., 1991, Drug Discrimination: Applications to Drug Abuse Research, 44
- Kuipers W., 1994, Drug Des. Discov., 11, 249
- Gallaher T. K., 1993, Med. Chem. Res., 3, 66
- Johnson M. P., 1994, Mol. Pharmacol., 45, 286
- Bergmann E. D., 1959, J. Chem. Soc., 1913, 1914
- Niemann C., 1941, J. Am. Chem. Soc., 63, 611
- Foreman M. M., 1994, J. Pharmacol. Exp. Ther., 270, 1281
- Litchfield J. T., 1949, J. Pharmacol. Exp. Ther., 96, 113
- Berg K. A., 1994, Mol. Pharmacol., 46, 484
- Watts V. J., 1996, Mol. Pharmacol., 50, 976
Cited by
Marine Indole Alkaloids: Potential New Drug Leads for the Control of Depression and Anxiety
Kochanowska-Karamyan, A. J., & Hamann, M. T. (2010) · Chemical Reviews · doi:10.1021/cr900211p · Cited by 2,040
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Self-citationNichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Self-citationThe Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
Madsen, M. K., Fisher, P. M., Burmester, D., Dyssegaard, A., Stenbæk, D. S., Kristiansen, S., Johansen, S. S., Lehel, S., Linnet, K., Svarer, C., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0324-9 · Cited by 517
Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens
Halberstadt, A. L., & Geyer, M. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.017 · Cited by 411
“By contrast, indolealkylamines are relatively non-selective for 5-HT receptors, displaying moderate to high affinity for 5-HT1 and 5-HT2 subtypes (Pierce and Peroutka, 1989; McKenna et al., 1990; Deliganis et al., 1991; Blair et al., 2000).”
BackgroundInfluentialKraehenmann, R., Preller, K. H., Scheidegger, M., Pokorny, T., Bosch, O. G., Seifritz, E., & Vollenweider, F. X. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.04.010 · Cited by 323
“Despite strong evidence that activation of 5HT2A receptors is necessary to mediate the hallucinogen action of psilocybin (16; 17), psilocin, the bioactive metabolite of psilocybin, also activates 5-HT1A and 5-HT2C receptors (55; 56).”
BackgroundKometer, M., Schmidt, A., Bachmann, R., Studerus, E., Seifritz, E., & Vollenweider, F. X. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.04.005 · Cited by 298
Psychedelics and the Human Receptorome
Ray, T. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009019 · Cited by 301
The hallucinogenic world of tryptamines: an updated review
Araújo, A. M., Carvalho, F., Bastos, M. D. L., Guedes de Pinho, P., & Carvalho, M. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1513-x · Cited by 292
“1 3 less selective, binding to a variety of 5-HT1 and 5-HT2 receptor subtypes (including 5-HT1A, 5-HT1B, 5-HT1C, 5-HT2A and 5-HT2C receptors) with different affinities (Blair et al. 2000; Fantegrossi et al. 2006, 2008a; McKenna et al. 1990; Peden et al. 1981; Strassman et al. 1996; Winter et al. 2000).”
BackgroundHalberstadt, A. L., Chatha, M., Klein, A. K., Wallach, J., & Brandt, S. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107933 · Cited by 278
Psilocybin – Summary of knowledge and new perspectives
Tylš, F., Páleníček, T., & Horáček, J. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.12.006 · Cited by 276
Mason, N. L., Kuypers, K. P. C., Müller, F., Reckweg, J., Tse, D. H. Y., Toennes, S. W., Hutten, N. R. P. W., Jansen, J. F. A., Stiers, P., Feilding, A., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0718-8 · Cited by 258
“Conversely, it has also been established that, along with the 5-HT2A receptor, psilocin also has a high affinity for the 5-HT1A receptor [70, 71].”
BackgroundQuednow, B. B., Kometer, M., Geyer, M. A., & Vollenweider, F. X. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.228 · Cited by 230
The behavioral pharmacology of hallucinogens
Fantegrossi, W. E., Murnane, K. S., & Reissig, C. J. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.018 · Cited by 225
“[174] Blair JB, Kurrasch-Orbaugh D, Marona-Lewicka D, Cumbay MG, Watts VJ, Barker EL, et al.”
Halberstadt, A. L., Koedood, L., Powell, S. B., & Geyer, M. A. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110388326 · Cited by 213
“Indoleamines, such as lysergic acid diethylamide (LSD), psilocin, N,N-dimethyltryptamine (DMT), and 5-methoxy-DMT (5-MeO-DMT) are non-selective serotonin (5-HT) receptor agonists that bind to 5-HT1A, 5-HT2A, and 5-HT2C receptors with moderateto-high affinity (Blair et al., 2000; McKenna et al., 1990; Pierce and Perout…”
BackgroundInfluentialPsychedelic-inspired drug discovery using an engineered biosensor
Dong, C., Ly, C., Dunlap, L. E., Vargas, M. V., Sun, J., Hwang, I.-W., Azinfar, A., Oh, W. C., Wetsel, W. C., Olson, D. E., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.043 · Cited by 213
Raval, N. R., Johansen, A., Donovan, L. L., Ros, N. F., Ozenne, B., Hansen, H. D., & Knudsen, G. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020835 · Cited by 200
“active compound psilocin which has a high affinity to 5-HT2AR, but also to other 5-HT receptors such as 5-HT1AR and 5-HT2CR [1,4,5].”
Raval, N. R., Johansen, A., Donovan, L. L., Ros, N. F., Ozenne, B., Hansen, H. D., & Knudsen, G. M. (2020) · doi:10.20944/preprints202011.0742.v1 · Cited by 200
Schmid, C. L., & Bohn, L. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1665-10.2010 · Cited by 175
“It has previously been very difficult to delineate the distinct neuropharmacological effects produced by serotonin and its psychoactive metabolites in vivo because many of the biogenic amines have higher affinities than serotonin at the 5-HT2AR (Glennon and Gessner, 1979; Blair et al., 2000).”
BackgroundPsilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans
Carter, O. L., Hasler, F., Pettigrew, J. D., Wallis, G. M., Liu, G. B., & Vollenweider, F. X. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0930-9 · Cited by 146
“1990) and 5-HT2C receptors (Blair et al. 2000); however, the role of these receptors is still unclear (for review, see Nichols 2004).”
BackgroundInfluentialDARK Classics in Chemical Neuroscience: Psilocybin
Geiger, H. A., Wurst, M. G., & Daniels, R. N. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00186 · Cited by 141
Pokorny, T., Preller, K. H., Krähenmann, R., & Vollenweider, F. X. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.01.005 · Cited by 154
“Psilocin binds with high affinity to 5-HT1A (Ki 49-567 nM, human cloned receptor, using 3H-8-OH-DPAT as comparator, Blair et al. (2000)) and 5-HT2A receptors (Ki 107 nM, human cloned receptor using 3H-Ketanserin, PDSP database https://pdspdb.”
MethodDark Classics in Chemical Neuroscience:N,N-Dimethyltryptamine (DMT)
Cameron, L. P., & Olson, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00101 · Cited by 172
“36 The isolation and puri fi cation of DMT also warrant some discussion.”
Chemistry and Structure–Activity Relationships of Psychedelics
Nichols, D. E. (2017) · Current topics in behavioral neurosciences · doi:10.1007/7854_2017_475 · Cited by 123
“It was recently found that it did not possess LSD- or DOI-like activity in a drug discrimination paradigm in rats (Blair et al. 2000).”
BackgroundSelf-citationEffect of Hallucinogens on Unconditioned Behavior
Halberstadt, A. L., & Geyer, M. A. (2016) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2016_466 · Cited by 106
“1990) and acts as a potent agonist at 5-HT1A receptors negatively coupled to adenylyl cyclase (Blair et al. 2000).”
BackgroundErkizia-Santamaría, I., Alles-Pascual, R., Horrillo, I., Meana, J. J., & Ortega, J. E. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113612 · Cited by 119
Enantioselective Total Synthesis of (−)-Citrinadin A and Revision of Its Stereochemical Structure
Bian, Z., Marvin, C. C., & Martin, S. F. (2013) · Journal of the American Chemical Society · doi:10.1021/ja405547f · Cited by 105
Investigation of the Structure–Activity Relationships of Psilocybin Analogues
Klein, A. K., Chatha, M., Laskowski, L. J., Anderson, E. I., Brandt, S. D., Chapman, S. J., McCorvy, J. D., & Halberstadt, A. L. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00176 · Cited by 109
Dunlap, L. E., Azinfar, A., Ly, C., Cameron, L. P., Viswanathan, J., Tombari, R. J., Myers-Turnbull, D., Taylor, J. C., Grodzki, A. C., Lein, P. J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01404 · Cited by 95
“2-(1H-indol-1-yl)-N,N-dimethylacetamide (31).”
Nichols, D. E., Frescas, S., Marona-Lewicka, D., & Kurrasch-Orbaugh, D. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020153s · Cited by 90
Self-citationSex differences and serotonergic mechanisms in the behavioural effects of psilocin
Tylš, F., Páleníček, T., Kadeřábek, L., Lipski, M., Kubešová, A., & Horáček, J. (2016) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000198 · Cited by 86
“According to ligand-binding studies, psilocin has a higher affinity to these receptors than to 5-HT2A receptors (Blair et al., 2000; Ray, 2010; Halberstadt and Geyer, 2011).”
BackgroundStructure–activity relationships of serotonin 5‐HT2Aagonists
Nichols, D. E. (2012) · Wiley Interdisciplinary Reviews Membrane Transport and Signalling · doi:10.1002/wmts.42 · Cited by 96
“Extension of the N(6)-methyl group of LSD to longer alkyl groups35 gives compounds that are more potent than LSD in vivo in rodent behavior and which in some cases have potency comparable to, or slightly greater than LSD in humans.”
Self-citationSakashita, Y., Abe, K., Katagiri, N., Kambe, T., Saitoh, T., Utsunomiya, I., Horiguchi, Y., & Taguchi, K. (2015) · Biological ^|^ Pharmaceutical Bulletin · doi:10.1248/bpb.b14-00315 · Cited by 81
Structural pharmacology and therapeutic potential of 5-methoxytryptamines
Warren, A. L., Lankri, D., Cunningham, M. J., Serrano, I. C., Parise, L. F., Kruegel, A. C., Duggan, P., Zilberg, G., Capper, M. J., Havel, V., et al. (2024) · Nature · doi:10.1038/s41586-024-07403-2 · Cited by 91
“In other cases, the Speeter–Anthony route was applied 30 .”
Duan, W., Cao, D., Wang, S., & Cheng, J. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00375 · Cited by 85
Psilocybin-induced stimulus control in the rat
Winter, J. C., Rice, K. C., Amorosi, D. J., & Rabin, R. A. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.06.003 · Cited by 86
“Although binding studies indicate that psilocybin has significant affinity for 5-HT 1A , 5-HT 2A , 5-HT 2c receptors (McKenna et al., 1990; Blair et al., 2000), complete antagonism by M100907 of the intermediate effects of psilocybin in rats trained with LSD [Fig.”
InfluentialHallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines
Winter, J. C. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1356-8 · Cited by 78
“Receptor binding data provided no clue in that Blair et al. (2000) observed KI values for psilocin of 49, 25, and 10 nM for 5-HT1A, 5-HT2A, and 5-HT2C receptors, respectively.”
BackgroundInfluentialPsilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy
Dodd, S., Norman, T. R., Eyre, H. A., Stahl, S. M., Phillips, A., Carvalho, A. F., & Berk, M. (2023) · CNS Spectrums · doi:10.1017/s1092852922000888 · Cited by 73
“Using cell preparations expressing 5HT2A or 5HT2C (rat) or 5HT1A (human) receptors a rank order of binding of psilocinwas 5HT2C>5HT2A>5HT1A.(26)A later study showed that in addition to binding to 5HT2A receptors psilocin bound to many other receptors, the increasing order of affinity being: 5HT2B, 5HT1D, dopamine D1,…”
Indole-Derived Arynes and Their Diels−Alder Reactivity with Furans
Buszek, K. R., Luo, D., Kondrashov, M. V., Brown, N., & VanderVelde, D. G. (2007) · Organic Letters · doi:10.1021/ol701595n · Cited by 71
Zamberlan, F., Sanz, C., Martínez Vivot, R., Pallavicini, C., Erowid, F., Erowid, E., & Tagliazucchi, E. (2018) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2018.00054 · Cited by 71
“The latter display higher selectivity for 5-HT 2A and 5-HT 2C receptors, while the behavioral and subjective effects of tryptamines are also likely to be influenced by 5-HT 1A agonism (McKenna et al., 1990; Blair et al., 2000; Nichols, 2016).”
BackgroundPharmacological Mechanism of the Non-hallucinogenic 5-HT 2A Agonist Ariadne and Analogs
Cunningham, M. J., Bock, H. A., Serrano, I. C., Bechand, B., Vidyadhara, D. J., Bonniwell, E. M., Lankri, D., Duggan, P., Nazarova, A. L., Cao, A. B., et al. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00597 · Cited by 67
Marona‐Lewicka, D., & Nichols, D. E. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.06.001 · Cited by 69
“Hallucinogens from different structural classes clearly mimicked LSD (Appel et al., 1982; Young et al., 1982; Colpaert et al., 1982; Oberlender et al., 1984; Cunningham et al., 1985; Freedman, 1986; Nichols, 1986; White, 1986; Arnt, 1989; Callahan and Appel, 1990; Huang et al., 1994; Monte et al., 1996, 1997; Chojnack…”
BackgroundSelf-citationZhuk, O., Jasicka-Misiak, I., Poliwoda, A., Kazakova, A., Godovan, V., Halama, M., & Wieczorek, P. (2015) · Toxins · doi:10.3390/toxins7041018 · Cited by 62
“There is some evidence that HTR takes place by means of activation of the 5-HT2A receptor [20–23].”
BackgroundWallach, J. V. (2009) · Medical Hypotheses · doi:10.1016/j.mehy.2008.07.052 · Cited by 59
“Neither DET nor 5-MeO-DMT have been evaluated with the APZ scale or any other hallucinogen rating scale such as the hallucinogen rating scale (HRS).”
BackgroundInfluentialBrandt, S. D., Kavanagh, P. V., Twamley, B., Westphal, F., Elliott, S. P., Wallach, J. V., Stratford, A., Klein, L. M., McCorvy, J. D., Nichols, D. E., et al. (2017) · Drug Testing and Analysis · doi:10.1002/dta.2222 · Cited by 60
Self-citationCorrection: Psychedelics and the Human Receptorome
Ray, T. S. (2010) · PLoS ONE · doi:10.1371/annotation/e580a864-cf13-40c2-9bd9-b9687a6f0fe4 · Cited by 58
Wey, S., Augustyniak, M. E., Cochran, E. D., Ellis, J. L., Fang, X., Garvey, D. S., Janero, D. R., Letts, L. G., Martino, A. M., Melim, T. L., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0611861 · Cited by 57
Some new psychoactive substances: Precursor chemicals and synthesis‐driven end‐products
Collins, M. (2011) · Drug Testing and Analysis · doi:10.1002/dta.315 · Cited by 54
Silver(I)-Promoted ipso-Nitration of Carboxylic Acids by Nitronium Tetrafluoroborate
Natarajan, P., Chaudhary, R., & Venugopalan, P. (2015) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.5b02133 · Cited by 53
Zhang, B., Zhao, S., Yang, D., Wu, Y., Ye, X., Cao, H., Huang, X., Cai, X., Sun, W. C., Ye, N., et al. (2020) · ACS Central Science · doi:10.1021/acscentsci.9b01125 · Cited by 51
Jin, L., Wang, X., Guo, H., Shi, X., Ren, X., & Huang, G. (2011) · Tetrahedron · doi:10.1016/j.tet.2011.12.002 · Cited by 48
Psilocybin, Lysergic Acid Diethylamide, Mescaline, and Drug-Induced Synesthesia
Brogaard, B. “., & Gatzia, D. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800212-4.00083-2 · Cited by 50
Fluorine-containing indoles: Synthesis and biological activity
Nosova, E. V., Lipunova, G. N., Чарушин, В. Н., & Чупахин, О. Н. (2018) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2018.05.012 · Cited by 47
Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans.
Cumming, P., Scheidegger, M., Dornbierer, D., Palner, M., Quednow, B. B., & Martin-Soelch, C. (2021) · Molecules · doi:10.3390/molecules26092451 · Cited by 43
“The corresponding Ki values against [123I]-DOI indicated ten-fold higher affinity at 5HT2A sites [10,14], which is presumably indicative of the greater competition between an agonist drug at agonist-labelled receptors, as has been established for the case of dopamine D2/3 receptors [46].”
BackgroundKlein, L. M., Cozzi, N. V., Daley, P. F., Brandt, S. D., & Halberstadt, A. L. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.02.028 · Cited by 43
“This is consistent with reports demonstrating that 4-hydroxy-DMT (psilocin) binds to 5-HT1A sites with 20-fold lower affinity compared to its 5-hydroxy isomer (bufotenine) or the 5-hydroxy O-methyl derivative (5-methoxy-DMT), whereas there is little difference between their 5-HT2A receptor affinities (McKenna et al.,…”
Donovan, L. L., Johansen, J. V., Ros, N. F., Jaberi, E., Línnet, K., Johansen, S. S., Ozenne, B., Issazadeh‐Navikas, S., Hansen, H. D., & Knudsen, G. M. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.11.013 · Cited by 50
Occurrence and use of hallucinogenic mushrooms containing psilocybin alkaloids
Andersson, C., Gry, J., & Kristinsson, J. (2009) · TemaNord · doi:10.6027/tn2008-606 · Cited by 41
Munir, S., Shahid, A., Aslam, B., Ashfaq, U. A., Akash, M. S. H., Ali, M. A., Almatroudi, A., Allemailem, K. S., Rajoka, M. S. R., & Khurshid, M. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/8836983 · Cited by 42
“In another study, this research group investigated how fluorination affects the hallucinogen-like activity of tryptamines [100].”
BackgroundTotal Synthesis of Exiguamines A and B Inspired by Catecholamine Chemistry
Sofiyev, V., Lumb, J., Volgraf, M., & Trauner, D. H. (2012) · Chemistry - A European Journal · doi:10.1002/chem.201103605 · Cited by 38
Bioactive Alkaloids of Hallucinogenic Mushrooms
Wieczorek, P. P., Witkowska, D., Jasicka-Misiak, І., Poliwoda, A., Oterman, M., & Zielińska, K. (2015) · Studies in natural products chemistry · doi:10.1016/b978-0-444-63462-7.00005-1 · Cited by 52
Complex discriminative stimulus properties of (+)lysergic acid diethylamide (LSD) in C57Bl/6J mice
Benneyworth, M. A., Smith, R. L., Barrett, R. J., & Sanders‐Bush, E. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2108-z · Cited by 38
“that, like LSD, it has a high affinity for the 5-HT1A receptor (Blair et al. 2000), and this common action at the 5-HT1A receptor may be responsible for the substitution to LSD.”
Pottie, E., & Stove, C. P. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15570 · Cited by 37
“…by means of a scintillation cocktail (Almaula et al., 1996; Berg, Clarke, Chen, et al., 1994; Berg et al., 1994, 1998; Berridge et al., 1982; Blair et al., 2000; Braden & Nichols, 2007; Braden et al., 2006; Chambers et al., 2001, 2003; Dowd et al., 2000; Ebersole et al., 2003; Egan et al.,…”
MethodOdland, A. U., Jessen, L., Kristensen, J. L., Fitzpatrick, C. M., & Andreasen, J. T. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107838 · Cited by 37
Halberstadt, A. L. (2016) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2016.01.005 · Cited by 35
“, 2010) or in the low micromolar range (Blair et al., 2000; Parrish and Nichols, 2006).”
Heteroaryl-O-glucosides as novel sodium glucose co-transporter 2 inhibitors. Part 1
Zhang, X., Urbanski, M. J., Patel, M., Zeck, R. E., Cox, G. G., Bian, H., Conway, B. R., Beavers, M. P., Rybczynski, P. J., & Demarest, K. T. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.08.067 · Cited by 34
Takaba, R., Ibi, D., Yoshida, K., Hosomi, E., Kawase, R., Kitagawa, H., Goto, H., Achiwa, M., Mizutani, K., Maeda, K., et al. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02778-x · Cited by 39
Guzzo, P. R., Buckle, R. N., Chou, M., Dinn, S. R., Flaugh, M. E., Kiefer, A. D., Ryter, K. T., Sampognaro, A. J., Tregay, S. W., & XU, Y. ‐. (2003) · The Journal of Organic Chemistry · doi:10.1021/jo020600b · Cited by 32
Aarrestad, I. K., Cameron, L. P., Fenton, E. M., Casey, A. B., Rijsketic, D. R., Patel, S. D., Sambyal, R., Johnson, S. B., Ly, C., Viswanathan, J., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02021-1 · Cited by 43
“The hemifuma-rate salt of 6-F-DET was synthesized as described previously 82 .”
Hernández-León, A., Escamilla-Orozco, R. I., Tabal-Robles, A. R., Martínez-Vargas, D., Romero-Bautista, L., Escamilla-Soto, G., Romero, O. S. G., Torres-Valencia, J. M., & González-Trujano, M. E. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117415 · Cited by 35
Kumar, V., Sharma, A., Sharma, A., & Sinha, A. K. (2007) · Tetrahedron · doi:10.1016/j.tet.2007.05.046 · Cited by 30
Serotonin and Serotonin Receptors in Hallucinogen Action
Halberstadt, A. L., & Nichols, D. E. (2010) · Handbook of behavioral neuroscience · doi:10.1016/s1569-7339(10)70103-x · Cited by 30
Self-citationWiens, K. R., Brooks, N. A. H., Riar, I., Greuel, B. K., Lindhout, I. A., & Klegeris, A. (2024) · Molecules · doi:10.3390/molecules29215084 · Cited by 30
“Psilocin displays a high level of affinity for the 5-HT 2A R but is also capable of binding to the 5-HT 2B R, 5-HT 2C R, and 5-HT 1A R isoforms, albeit with a lower level of affinity [36,37].”
BackgroundAboharb, F., Davoudian, P. A., Shao, L.-X., Liao, C., Rzepka, G. N., Wojtasiewicz, C., Indajang, J., Dibbs, M., Rondeau, J. A., Sherwood, A. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56850-6 · Cited by 27
“Concordantly, 6-136 fluoro-DET provided ineffective as a substitute compound for rats trained to discriminate LSD or 2,5-dimethoxy-4-iodoamphetamine (known as DOI) 64, 68 .”
Chen, Y., Liu, J., Yao, Y., Yan, H., & Su, R. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1021729 · Cited by 24
“Psilocin was found to exhibit a high affinity for 5-HT1A receptors, with Ki = 49 nM (Blair et al., 2000).”
BackgroundChronic Treatment With Psilocybin Decreases Changes in Body Weight in a Rodent Model of Obesity
Huang, J. Y., Pham, M. M., Panenka, W. J., Honer, W. G., & Barr, A. M. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.891512 · Cited by 20
Heal, D. J., Gosden, J., Smith, S. L., & Atterwill, C. K. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109375 · Cited by 20
“…and psilocin (the psychoactive metabolite of psilocybin), report no effect on the extracellular levels of 5-HT or dopamine in various brain regions (Bogdanov et al., 1991; Gudelsky et al., 1994; Sakashita et al., 2015), others have observed increases in dopamine in the nucleus accumbens (Sakashita…”
BackgroundRediscovering Psilocybin as an Antidepressive Treatment Strategy
Zeiss, R., Gahr, M., & Graf, H. (2021) · Pharmaceuticals · doi:10.3390/ph14100985 · Cited by 32
da Silva, M. A. V. R., & Ferreira, A. I. M. C. L. (2008) · The Journal of Chemical Thermodynamics · doi:10.1016/j.jct.2008.09.012 · Cited by 17
Xue, C., Li, J., Yu, L. X., Maule, F., Chang, L., Gallant, J. A., Press, D. J., Raithatha, S. A., Hagel, J. M., & Facchini, P. J. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105231 · Cited by 19
“Literature regarding impact of 6-fluorination on the binding of indolethylamines to the 5-HT2A receptor have shown enhanced affinity; for example, in comparing 6-fluoroDMT (Ki 866 nM) to DMT (Ki 2323 nM) (15) or comparing 6-fluoro-psilocin (Ki 13 nM) to psilocin (Ki 25 nM) (43).”
Background5-Hydroxytryptamine receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
Andrade, R., Barnes, N. M., Baxter, G. S., Bockaert, J., Branchek, T. A., Butler, A. S., Cohen, M. L., Dumuis, A., Eglen, R. M., Göthert, M., et al. (2019) · IUPHAR/BPS Guide to Pharmacology CITE · doi:10.2218/gtopdb/f1/2019.4 · Cited by 18
A novel fluorinated tryptamine with highly potent serotonin 5-HT1A receptor agonist properties
Laban, U., Kurrasch‐Orbaugh, D. M., Marona‐Lewicka, D., & Nichols, D. E. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00062-2 · Cited by 15
Self-citationGlatfelter, G. C., Clark, A. A., Cavalco, N. G., Landavazo, A., Partilla, J. S., Naeem, M., Golen, J. A., Chadeayne, A. R., Manke, D. R., Blough, B. E., et al. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00513 · Cited by 17
Ryu, I. S., Kim, O., Lee, Y. E., Kim, J., Li, Z., Kim, T. W., Lim, R.-N., Lee, Y. J., Cheong, J. H., Kim, H. J., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134631 · Cited by 15
“Addition of fluorine (a chemical element) to ring structures of drugs can influence the metabolism and distribution of the original drug molecules in the body and can dramatically change their biological activities [11].”
BackgroundMeccia, J., Lopez, J., & Bagot, R. C. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06297-0 · Cited by 14
Neurobiology of the Effects of Psilocybin in Relation to Its Potential Therapeutic Targets
Tylš, F., Páleníček, T., & Horáček, J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800212-4.00073-x · Cited by 15
Discriminative Stimulus Effects of Substituted Tryptamines in Rats
Gatch, M. B., Hoch, A. C., & Carbonaro, T. M. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00173 · Cited by 13
Bidylo, T. I., & Yurovskaya, M. A. (2008) · Chemistry of Heterocyclic Compounds · doi:10.1007/s10593-008-0057-x · Cited by 13
Binding Properties of Dipropyltryptamine at the Human 5-HT1a Receptor
Thiagaraj, H. V., Russo, E. B., Burnett, A., Goldstein, E., Thompson, C. M., & Parker, K. K. (2005) · Pharmacology · doi:10.1159/000085649 · Cited by 15
Zhang, M., Yang, Y., Yang, Z., Wen, X., Zhang, C., Xiao, P., Wang, Y., Sun, J., Wang, X., & Wang, X. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117049 · Cited by 12
Abbas, E. M. H., Dawood, D. H., Farghaly, T. A., El‐Hag, F. A. A., & Ali, M. M. (2017) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.2794 · Cited by 11
Synthesis and structure of fluoroindole nucleosides
Božilović, J., Bats, J. W., & Engels, J. W. (2007) · Canadian Journal of Chemistry · doi:10.1139/v07-020 · Cited by 11
Clinical and preclinical evidence of psilocybin as antidepressant. A narrative review
Erkizia-Santamaría, I., Horrillo, I., Meana, J. J., & Ortega, J. E. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111249 · Cited by 13
“Data obtained from Blair et al., 2000; Geiger et al., 2018; Glatfelter et al., 2022; Halberstadt and Geyer, 2011; Rickli et al., of fear or anxiety reactions for the upcoming hallucinogen session.”
Bildziukevich, U., Kvasnicová, M., Šaman, D., Rárová, L., & Wimmer, Z. (2021) · Plants · doi:10.3390/plants10102082 · Cited by 9
“At present, the importance of fluorine-bearing compounds has been much higher in treating cancer [26] or inflammation, and it has also appeared in medicaments against depression and supporting the central nervous system [18,21,27].”
BackgroundJensen, N. (2005) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-2111 · Cited by 11
The therapeutic potential of psilocybin beyond psychedelia through shared mechanisms with ketamine
Park, D., Lee, G., Lee, W.-G., Kim, B. S., Lee, Y., & Kim, J. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03100-2 · Cited by 14
Tyagi, R., Saraf, T. S., & Canal, C. E. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00137 · Cited by 8
Fortwengel, G. (2003) · KARGER eBooks · doi:10.1159/000074701 · Cited by 7
Pazur, E. J., Kalatanova, A. V., Tasker, N. R., Vainionpää, K., Leinonen, H., & Wipf, P. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00130 · Cited by 5
Fluorine substituted methoxyphenylalkyl amides as potent melatonin receptor agonists
Tsotinis, A., Kompogennitaki, R., Papanastasiou, I. P., Garratt, P. J., Bocianowska‐Zbrog, A., & Sugden, D. (2019) · MedChemComm · doi:10.1039/c8md00604k · Cited by 6
Metadata
- Authors
- Blair, J. B., Kurrasch-Orbaugh, D., Marona-Lewicka, D., Cumbay, M. G., Watts, V. J., Barker, E. L., & Nichols, D. E.
- Affiliations
- Purdue University West Lafayette (US)
- Department of Medicinal Chemistry and Molecular Pharmacology, School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, Indiana 47907
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2000-10-19
- Volume
- 43
- Issue
- 24
- Pages
- 4701-4710
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1972426098
- Cited by
- 131
- References
- 56
- Citations by year
- 2026: 9 · 2025: 9 · 2024: 7 · 2023: 7 · 2022: 7 · 2021: 5 · 2020: 11 · 2019: 4 · 2018: 5 · 2017: 4 · 2016: 7 · 2015: 6 · 2014: 2 · 2013: 5 · 2012: 5
- FWCI
- 2.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (DA 02189)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- fluorination, 5-HT2A receptor, 5-HT2C receptor, 5-HT1A receptor, drug discrimination, 8-OH-DPAT
- MeSH terms
- Cyclic AMP, Animals, Binding, Competitive, Discrimination Learning, Drug Evaluation, Preclinical, Fluorine, Colforsin, Hallucinogens, Cricetinae, Humans, Hydrolysis, Phosphatidylinositols, Radioligand Assay, Receptors, Serotonin, Structure-Activity Relationship, Tryptamines, CHO Cells, 3T3 Cells, Serotonin Receptor Agonists, Receptors, Serotonin, 5-HT1, Receptor, Serotonin, 5-HT2A, Receptor, Serotonin, 5-HT2C, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.